Squarepoint Ops LLC Decreases Position in Voyager Therapeutics, Inc. (NASDAQ:VYGR)

Squarepoint Ops LLC lowered its stake in shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) by 45.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 38,650 shares of the company’s stock after selling 32,074 shares during the period. Squarepoint Ops LLC owned 0.07% of Voyager Therapeutics worth $219,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of VYGR. Vanguard Group Inc. grew its stake in Voyager Therapeutics by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 3,215,441 shares of the company’s stock valued at $18,232,000 after buying an additional 29,014 shares in the last quarter. Farallon Capital Management LLC grew its stake in Voyager Therapeutics by 12.2% in the 4th quarter. Farallon Capital Management LLC now owns 2,570,700 shares of the company’s stock valued at $14,576,000 after buying an additional 278,700 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in Voyager Therapeutics by 24.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,380,615 shares of the company’s stock valued at $7,828,000 after buying an additional 275,571 shares in the last quarter. Geode Capital Management LLC grew its stake in Voyager Therapeutics by 0.4% in the 4th quarter. Geode Capital Management LLC now owns 1,084,238 shares of the company’s stock valued at $6,149,000 after buying an additional 4,729 shares in the last quarter. Finally, Northern Trust Corp grew its stake in Voyager Therapeutics by 3.0% in the 4th quarter. Northern Trust Corp now owns 418,745 shares of the company’s stock valued at $2,374,000 after buying an additional 12,374 shares in the last quarter. Hedge funds and other institutional investors own 48.03% of the company’s stock.

Insider Transactions at Voyager Therapeutics

In other news, CEO Alfred Sandrock sold 10,885 shares of Voyager Therapeutics stock in a transaction on Wednesday, April 2nd. The shares were sold at an average price of $3.43, for a total transaction of $37,335.55. Following the completion of the sale, the chief executive officer now directly owns 430,931 shares of the company’s stock, valued at approximately $1,478,093.33. The trade was a 2.46% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 6.39% of the stock is currently owned by insiders.

Voyager Therapeutics Price Performance

Shares of NASDAQ:VYGR opened at $3.54 on Friday. The firm has a fifty day moving average price of $3.23 and a two-hundred day moving average price of $4.45. Voyager Therapeutics, Inc. has a one year low of $2.65 and a one year high of $9.55. The company has a market cap of $195.89 million, a price-to-earnings ratio of 4.99 and a beta of 0.82.

Voyager Therapeutics (NASDAQ:VYGR) last announced its earnings results on Tuesday, May 6th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.18). The company had revenue of $6.47 million during the quarter, compared to analysts’ expectations of $13.55 million. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. Equities research analysts expect that Voyager Therapeutics, Inc. will post -0.91 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

VYGR has been the subject of a number of recent research reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Voyager Therapeutics in a research note on Wednesday, March 12th. Wedbush reiterated an “outperform” rating on shares of Voyager Therapeutics in a research note on Wednesday, March 12th. Canaccord Genuity Group reduced their price objective on shares of Voyager Therapeutics from $14.00 to $12.00 and set a “buy” rating for the company in a research note on Thursday, March 13th. Wells Fargo & Company set a $10.00 price objective on shares of Voyager Therapeutics and gave the company an “overweight” rating in a research note on Wednesday, March 12th. Finally, HC Wainwright reiterated a “buy” rating and issued a $30.00 price objective on shares of Voyager Therapeutics in a research note on Tuesday, April 8th. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $13.39.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.